Clinical Trials in France / NCT06805409
Recruiting
Observational
VExUS in Ards Patients and Association with AKI
NCT06805409 · tracked via the Priya Life Science France tracker
Condition(s) studied
Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Study summary
A single-center prospective observational study will be conducted with the aim of determining the prevalence of venous congestion during ARDS using venous Doppler and the VExUS score.
Eligibility
Inclusion Criteria:
* Patients ≥18 years old
* Moderate to severe ARDS according to the Berlin definition
* Requiring catecholamine support
* Undergoing invasive mechanical ventilation for less than 48 hours
Exclusion Criteria:
* Patients presenting with acute kidney injury KDIGO III requiring renal replacement therapy before the initial ultrasound evaluation
* Requirement for veno-venous or veno-arterial ECMO circulatory support before inclusion
* Patients with end-stage chronic kidney disease, on dialysis, and/or kidney transplant recipients
* History of Child C cirrhosis and/or liver transplantation and/or portal hypertension
* History of portal thrombosis
* Known history of pulmonary hypertension
* Pregnant women
* Patients under legal protection
* Patients who have expressed opposition to participating in the research
Primary outcome measure(s)
- Proportion of VExUS score ≥ 1 within 48 hours of invasive mechanical ventilation. — 48 hours, 7 days after mechanical ventilation
Quantification of the VExUS score from the measurement of the inferior vena cava size, an assessment of suprahepatic venous flow, portal venous flow and intra-renal venous.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Armand MEKONTSO DESSAP | Créteil | Val de Marne | Recruiting |
More Assistance Publique - Hôpitaux de Paris trials in France
Kinematic Analysis of Latissimus Dorsi Transfer Results for Shoulder External Rotation Resuscitation
Starting soon
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06805409 on ClinicalTrials.gov ↗ ← All trials in France